Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?

Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? Surg Oncol Clin N Am. 2018 Jan;27(1):141-153 Authors: Chaudhary LN, Wilkinson KH, Kong A Abstract Progress in the treatment of triple-negative breast cancer remains an important challenge. Given the aggressive biology and high risk of distant recurrence, systemic chemotherapy is warranted in most patients. Neaodjuvant chemotherapy benefits patients with locally advanced disease by downsizing the tumor and increasing the probability of breast-conserving surgery. Clinical and pathologic responses provide important prognostic information, which makes neoadjuvant therapy an attractive approach for all patients with triple-negative breast cancer. Clinical research in the neoadjuvant setting is focused on improvement in pathologic complete response rates and outcomes of patients with residual disease. PMID: 29132557 [PubMed - in process]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Surg Oncol Clin N Am Source Type: research